Arzneimittelreaktionen bei antineoplastischen Substanzen
作者： L.M. Ehmann , H. Schrumpf , P.A. Gerber , B. Homey
DOI: 10.1007/S00105-013-2699-6
关键词:
摘要: In recent years, several new classes of compounds have successfully been established in the treatment cancer. They selectively inhibit disturbed signaling pathways or induce anti-tumor immune responses. These novel targeted cancer drugs show a favorable safety profile compared to conventional chemotherapeutic agents. The most important side effects these anticancer agents include cutaneous reactions and occur time-dependant manner class-specific patterns. this review article, we compare epidermal growth factor inhibitors (EGFRI), multikinase (MKI), BRAF (BRAFI), mTor (mTorI) checkpoint discuss severity-adapted management strategies.
springer.com
sci-hub.se 参考文章(31)
L M Ehmann, T Ruzicka, A Wollenberg, Cutaneous side-effects of EGFR inhibitors and their management. Skin therapy letter. ,vol. 16, pp. 1- 3 ,(2011)
Katharina C. Kähler, Axel Hauschild, Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma JDDG: Journal der Deutschen Dermatologischen Gesellschaft. ,vol. 9, pp. 277- 286 ,(2011) , 10.1111/J.1610-0387.2010.07568.X
P.A. Gerber, B.A. Buhren, S. Kürle, B. Homey, Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors Hautarzt. ,vol. 61, pp. 654- 661 ,(2010) , 10.1007/S00105-010-1943-6
Ralf Gutzmer, Jürgen C. Becker, Alexander Enk, Claus Garbe, Axel Hauschild, Martin Leverkus, Georg Reimer, Regina Treudler, Athanasios Tsianakas, Claas Ulrich, Andreas Wollenberg, Bernhard Homey, Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician JDDG: Journal der Deutschen Dermatologischen Gesellschaft. ,vol. 9, pp. 195- 202 ,(2011) , 10.1111/J.1610-0387.2010.07561.X
Lisa Zimmer, Julia Vaubel, Elisabeth Livingstone, Dirk Schadendorf, Side effects of systemic oncological therapies in dermatology Journal Der Deutschen Dermatologischen Gesellschaft. ,vol. 10, pp. 475- 486 ,(2012) , 10.1111/J.1610-0387.2012.07942.X
Jae-Cheol Jo, Yong Sang Hong, Kyu-pyo Kim, Jae-Lyun Lee, Hwa Jung Kim, Mi-Woo Lee, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim, Jong Hoon Kim, Tae Won Kim, Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer European Journal of Dermatology. ,vol. 23, pp. 77- 82 ,(2013) , 10.1684/EJD.2012.1899
J. R. Infante, G. S. Falchook, D. P. Lawrence, J. S. Weber, R. F. Kefford, J. C. Bendell, R. Kurzrock, G. Shapiro, R. R. Kudchadkar, G. V. Long, H. A. Burris, K. B. Kim, A. Clements, S. Peng, B. Yi, A. J. Allred, D. Ouellet, K. Patel, P. F. Lebowitz, K. T. Flaherty, Phase I/II study to assess safety, pharmacokinetics, and efficacy of the oral MEK 1/2 inhibitor GSK1120212 (GSK212) dosed in combination with the oral BRAF inhibitor GSK2118436 (GSK436). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.18_SUPPL.CRA8503
Courtney J. Ensslin, Alyx C. Rosen, Shenhong Wu, Mario E. Lacouture, Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis Journal of the American Academy of Dermatology. ,vol. 69, pp. 708- 720 ,(2013) , 10.1016/J.JAAD.2013.06.038
Wilfried Budach, Edwin Bölke, Bernhard Homey, Severe cutaneous reaction during radiation therapy with concurrent cetuximab. The New England Journal of Medicine. ,vol. 357, pp. 514- 515 ,(2007) , 10.1056/NEJMC071075
Cristina Gomez-Fernandez, Benjamin C. Garden, Shenwong Wu, Darren R. Feldman, Mario E. Lacouture, The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. European Journal of Cancer. ,vol. 48, pp. 340- 346 ,(2012) , 10.1016/J.EJCA.2011.11.028